Literature DB >> 10798068

Renal transplantation in infants and children.

A Moudgil1, S C Jordan.   

Abstract

Renal transplantation is the treatment of choice in children with end stage renal disease. Advances in organ retrieval and preservation, improved surgical techniques and postsurgical care, newer immunosuppressive drugs and prevention and treatment of infections have significantly improved survival of the renal allograft. The absolute requirements for a transplant are compatible blood group and a negative cytotoxic crossmatch. HLA identical grafts have a longer half-life than those that are less well matched. The immunosuppressive drugs most often used are cyclosporin A (or tacrolimus), azathioprine (or mycophenolate mofetil) and prednisone. Complications following transplantation include episodes of acute rejection, serious bacterial and viral infections, hypertension and recurrence of primary disease in the allograft. Each centre must have standard protocols for pre-transplant evaluation, and monitoring during surgery and in the post-operative period. Socio-economic factors should be evaluated before offering renal transplantation to children in developing countries.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10798068     DOI: 10.1007/bf02761217

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  18 in total

1.  Growth-hormone treatment of renal transplant recipients: the National Cooperative Growth Study experience--a report of the National Cooperative Growth Study and the North American Pediatric Renal Transplant Cooperative Study.

Authors:  M Mentser; T J Breen; E K Sullivan; R N Fine
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

Review 2.  Immunoregulatory drugs: mechanistic basis for use in organ transplantation.

Authors:  M Suthanthiran; T B Strom
Journal:  Pediatr Nephrol       Date:  1997-10       Impact factor: 3.714

3.  Cytomegalovirus prophylaxis in solid organ transplant recipients.

Authors:  R Patel; D R Snydman; R H Rubin; M Ho; M Pescovitz; M Martin; C V Paya
Journal:  Transplantation       Date:  1996-05-15       Impact factor: 4.939

4.  Hepatitis C in renal transplantation.

Authors:  G G Vosnides
Journal:  Kidney Int       Date:  1997-09       Impact factor: 10.612

5.  Treatment of recurrent focal segmental glomerulosclerosis with high-dose cyclosporine A and plasmapheresis.

Authors:  J Mowry; J Marik; A Cohen; R Hogg; S Sahney; R Ettenger
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

Review 6.  Infectious disease complications of renal transplantation.

Authors:  R H Rubin
Journal:  Kidney Int       Date:  1993-07       Impact factor: 10.612

7.  Tacrolimus in pediatric renal transplantation.

Authors:  R Shapiro; V P Scantlebury; M L Jordan; C Vivas; H A Gritsch; D Ellis; N Gilboa; S Lombardozzi-Lane; W Irish; J J Fung; T R Hakala; R L Simmons; T E Starzl
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

8.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

Authors:  H W Sollinger
Journal:  Transplantation       Date:  1995-08-15       Impact factor: 4.939

Review 9.  Recurrent primary disease and de novo nephritis following renal transplantation.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

10.  Cyclosporine dosing and its relationship to outcome in pediatric renal transplantation.

Authors:  W E Harmon; E K Sullivan
Journal:  Kidney Int Suppl       Date:  1993-10       Impact factor: 10.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.